Eli Lilly and NVIDIA both reported strong quarterly results, with Lilly growing 47.7% driven by obesity drugs Mounjaro and Zepbound, and NVIDIA soaring 105.8% on AI data center demand. Lilly focuses on expanding its pharmaceutical portfolio and manufacturing capacity, while NVIDIA leads in AI infrastructure with massive third-party capital backing. Analysts favor NVIDIA for its rapid revenue growth and platform strategy despite some margin risks, while Lilly offers defensive exposure with dividend growth. The choice for a $10,000 investment in 2026 depends on whether investors prioritize high growth in AI or steady gains in healthcare innovation.
Eli Lilly announced positive one-year Phase 3 results for Omvoh (mirikizumab-mrkz) in children aged 6 to 17 with moderately to severely active ulcerative colitis. In the SHINE-2 study, 81% of patients responded at 12 weeks, and 50% of responders achi...
Eli Lilly announced new clinical data presentations at the 2026 European Society for Medical Oncology (ESMO) Congress, featuring updates on several investigational and approved cancer therapies. Key highlights include Phase 1 data for sofetabart mipi...
Eli Lilly transformed from a traditional insulin maker into a pharmaceutical giant, driven by its obesity drug Tirzepatide, sold as Mounjaro and Zepbound. These drugs generated $14.9 billion in Q2 2026 alone, capturing 60% of U.S. obesity prescriptio...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
Eli Lilly will announce its third-quarter 2026 financial results on October 29, 2026, followed by a conference call at 10 a.m. Eastern time to discuss the company's performance. The call will be accessible via a live webcast on Lilly's investor websi...
